Skip to main content
Contact Us
Subscribe
E-Edition
52°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Assembly Biosciences, Inc.
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
November 07, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
September 23, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
August 08, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
July 15, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
June 18, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Announces $12.6 Million in Equity Financings
June 17, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
June 10, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024
June 05, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
May 22, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
May 08, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
March 28, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Announces Effective Date of Reverse Stock Split
February 08, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Provides Anticipated Development Milestones for 2024
January 04, 2024
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
November 10, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
November 08, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
November 08, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
October 11, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
October 02, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
September 19, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates
August 09, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
July 17, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023
June 21, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
June 07, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
May 23, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
May 04, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update
April 18, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights
March 22, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes
February 15, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334
December 19, 2022
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Tickers
ASMB
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.